Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Key Inclusion Criteria:

- Adults with AML in need of treatment

- Group A : Individuals > 18 years of age with previously untreated AML who are able and
should receive up to 2 cycles of induction chemotherapy with 7+3 as determined by the
treating physician

- Group B: Individuals > 70 years of age with previously untreated AML or individuals <
70 years of age with previously untreated AML who refuse or are unable to receive
cytarabine as determined by the treating physician

- Group C: Cohort C1A: Subjects age ≥ 18 years with relapsed/refractory AML by WHO
criteria; Cohort C2: Subjects age ≥ 18 years with relapsed/refractory AML with MLL;
Cohort C3: Subjects with previously untreated AML by WHO criteria and who would have
met disease eligibility criteria for Group A or B but refuse or are unable to receive
chemotherapy and hypomethylating agent as determined by the treating physician

Key Exclusion Criteria:

- Known active central nervous system or leptomeningeal lymphoma

- Subjects with acute promyelocytic leukemia (M3)

- Treatment with proton pump inhibitors (PPIs) within 7 days prior to enrollment.

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.